Can diphenhydramine (antihistamine) be administered intramuscularly (IM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Diphenhydramine Be Given Intramuscularly?

Yes, diphenhydramine can be safely administered intramuscularly (IM) and is FDA-approved for this route of administration. 1

FDA-Approved Routes and Dosing

Diphenhydramine hydrochloride injection is explicitly indicated for both intravenous and intramuscular administration when the oral form is impractical. 1

Adult IM Dosing:

  • 10-50 mg deep intramuscularly, up to 100 mg if required 1
  • Maximum daily dosage: 400 mg 1
  • The injection should be given deep into the muscle 1

Pediatric IM Dosing:

  • 5 mg/kg/24 hours or 150 mg/m²/24 hours divided into four doses 1
  • Maximum daily dosage: 300 mg 1
  • Not recommended for premature infants and neonates 1

Clinical Context for IM Administration

Anaphylaxis Management:

  • 1-2 mg/kg or 25-50 mg per dose administered intramuscularly or intravenously 2
  • The American Academy of Allergy, Asthma, and Immunology recommends this dosing for anaphylaxis 2
  • Combination with H2-blockers (ranitidine) is superior to diphenhydramine alone in managing anaphylactic reactions 3, 2

Pretreatment for Radiocontrast Media Reactions:

  • 50 mg intramuscularly 1 hour before radiocontrast media administration in patients with prior anaphylactoid reactions 3
  • For emergency procedures: 50 mg IM 1 hour before contrast administration (combined with IV hydrocortisone) 3

Important Safety Considerations

Onset and Duration:

  • Onset of action: several minutes when given parenterally 3, 2
  • Duration of effect: 4-6 hours 3, 2

Adverse Effects to Monitor:

  • Anticholinergic effects: confusion, delirium (especially in elderly), dry mouth, blurred vision, urinary retention 3, 2
  • Cardiovascular effects: hypotension, tachycardia 3
  • Respiratory depression (particularly when combined with other CNS depressants) 3
  • QT prolongation has been reported with chronic use 4

Critical Pitfalls:

Avoid rapid IV administration - when given intravenously, the rate should generally not exceed 25 mg/min to minimize hypotension risk 1. While IM administration avoids this specific concern, it's important to distinguish between routes.

Risk of myonecrosis with repeated deep IM injections - one case report documented severe myonecrosis at injection sites with chronic IM diphenhydramine abuse 4. This is distinct from subcutaneous administration, which has been shown safe in hospice settings (648 injections without adverse cutaneous reactions) 5.

Pediatric cardiovascular risk - one case report documented cardiac arrest in a 3-month-old infant following 1.25 mg/kg IV diphenhydramine, highlighting the need for caution in vulnerable populations 6.

Not recommended for elderly patients due to high anticholinergic burden and increased risk of confusion, falls, and delirium 2.

Alternative Routes When IM is Impractical

If IM access is difficult but parenteral administration is needed, subcutaneous administration has been demonstrated safe in hospice settings with no reported skin necrosis in 648 injections 5. This contradicts older case reports from the 1990s that described necrosis with subcutaneous use for local anesthesia 5.

References

Guideline

Diphenhydramine Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Safe Use of Subcutaneous Diphenhydramine in the Inpatient Hospice Unit.

The American journal of hospice & palliative care, 2017

Research

Cardiac Arrest Following the Administration of Intravenous Diphenhydramine for Sedation to an Infant With Congenital Heart Disease.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.